- Home
- ICON vs MBIO Comparison
ICON vs MBIO Comparison
Compare ICON & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- MBIO
- Stock Information
- Founded
- ICON 2023
- MBIO 2015
- Country
- ICON Greece
- MBIO United States
- Employees
- ICON N/A
- MBIO N/A
- Industry
- ICON
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- MBIO Health Care
- Exchange
- ICON Nasdaq
- MBIO Nasdaq
- Market Cap
- ICON 5.2M
- MBIO 4.7M
- IPO Year
- ICON 2024
- MBIO N/A
- Fundamental
- Price
- ICON $2.89
- MBIO $2.65
- Analyst Decision
- ICON Strong Buy
- MBIO
- Analyst Count
- ICON 1
- MBIO 0
- Target Price
- ICON $4.50
- MBIO N/A
- AVG Volume (30 Days)
- ICON 3.4M
- MBIO 17.4M
- Earning Date
- ICON 09-09-2025
- MBIO 08-12-2025
- Dividend Yield
- ICON 332.15%
- MBIO N/A
- EPS Growth
- ICON N/A
- MBIO N/A
- EPS
- ICON N/A
- MBIO N/A
- Revenue
- ICON $5,474,000.00
- MBIO N/A
- Revenue This Year
- ICON $51.78
- MBIO N/A
- Revenue Next Year
- ICON $51.90
- MBIO N/A
- P/E Ratio
- ICON N/A
- MBIO N/A
- Revenue Growth
- ICON 16.93
- MBIO N/A
- 52 Week Low
- ICON $1.60
- MBIO $0.89
- 52 Week High
- ICON $154.00
- MBIO $24.00
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- MBIO 61.22
- Support Level
- ICON N/A
- MBIO $2.62
- Resistance Level
- ICON N/A
- MBIO $3.68
- Average True Range (ATR)
- ICON 0.00
- MBIO 0.59
- MACD
- ICON 0.00
- MBIO 0.18
- Stochastic Oscillator
- ICON 0.00
- MBIO 28.77
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.